ABL1 is an inclusion eligibility criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

BRAF is an inclusion eligibility criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

DDR2 is an inclusion eligibility criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains DDR2 status and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

EGFR is an inclusion eligibility criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

EPHA2 is an inclusion eligibility criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains EPHA2 status and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

ERBB2 is an inclusion eligibility criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

ERBB4 is an inclusion eligibility criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB4 status and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

FGFR1 is an inclusion eligibility criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR1 status and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

FGFR2 is an inclusion eligibility criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT1 is an inclusion eligibility criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT4 is an inclusion eligibility criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FLT4 status and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

FRK is an inclusion eligibility criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FRK status and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

IDH1 is an inclusion eligibility criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

KDR is an inclusion eligibility criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains KDR status and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

KIT is an inclusion eligibility criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains KIT status and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

MAPK11 is an inclusion eligibility criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MAPK11 status and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

PDGFRA is an inclusion eligibility criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

PDGFRB is an inclusion eligibility criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

RAF1 is an inclusion eligibility criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RAF1 status and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

RET is an inclusion eligibility criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RET status and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

TEK is an inclusion eligibility criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains TEK status and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

TRNAK2 is an inclusion eligibility criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains TRNAK2 status and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

VEGFA is an inclusion eligibility criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains VEGFA status and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

VEGFB is an inclusion eligibility criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains VEGFB status and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

VEGFC is an inclusion eligibility criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains VEGFC status and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].